- Details
- Andrea Miyahira and Alex Wyatt discuss a study on de novo metastatic prostate cancer, revealing its genomic complexity through multiregion sampling. Published in Nature Cancer, the research highlights the polyclonality of the disease and its implications for clinical genotyping. By examining multiple regions from patients' prostates and lymph nodes, the study uncovers significant genomic heterogen...
|
- Details
- Andrea Miyahira hosts Johann De Bono to discuss his group's paper on reversing prostate cancer therapy resistance by targeting myeloid chemotaxis. Dr. De Bono, with contributions from his team, including Christina Guo and Adam Sharp, explores the role of inflammation in prostate cancer. The study focuses on how stressed cancer cells attract inflammatory cells, which can then support tumor growth a...
|
- Details
- Jindan Yu delves into her team's research on "Chemokine Receptor CXCR7 Activates Aurora Kinase A and Promotes Neuroendocrine Prostate Cancer Growth," published in the Journal of Clinical Investigation. Dr. Yu's study began with the observation that CXCR7, an atypical chemokine receptor, is upregulated in enzalutamide-resistant prostate cancer cells. The research reveals that CXCR7, unlike the bett...
|
- Details
- Andrea Miyahira talks with Louise Emmett who shares her unconventional journey into nuclear medicine, sparked by a contrarian spirit and a suggestion against pursuing the field. Initially specializing in nuclear cardiology in Canada, she shifted to theranostics and nuclear medicine, driven by the dynamic growth in these areas. Dr. Emmett discusses the challenges and excitement of running clinical...
|
- Details
- Andrea Miyahira hosts a discussion with Veda Giri, Ayesha Shafi, and Claire Fletcher, members of the PCF Women in Science Forum Organizing Committee. The forum aims to build a strong network of women in prostate cancer research and address gender inequities in science. Key themes include negotiation strategies for women, with insights from law professor Stacy Lee; amplifying women's voices in rese...
|
- Details
- Patrick Pilié discusses his team's paper on SPOP mutations in prostate cancer and their therapeutic vulnerabilities, especially to PARP inhibitor-induced growth suppression. The paper, published in Clinical Cancer Research, explores the heterogeneous nature of prostate cancer treatment responses, particularly in metastatic castrate-resistant prostate cancer with SPOP mutations. These mutations sho...
|
- Details
- Andrea Miyahira engages with Scott Dehm to discuss his research on AR gene alterations in endocrine therapy-resistant prostate cancer. In collaboration with teams from multiple universities, including Princeton and UCSF, Dr. Dehm examines the frequent AR gene alterations in castration-resistant prostate cancers. Utilizing linked-read DNA sequencing, the study confirms that a subset of these cancer...
|
- Details
- Andrea Miyahira engages with Akash Patnaik on his team's research on tumor cell lactate-generating signaling pathways in aggressive-variant prostate cancer. Dr. Patnaik highlights the challenges associated with treating PTEN deficient prostate cancers, which constitute about 50% of metastatic castrate-resistant prostate cancer cases resistant to standard treatments. His research emphasizes the rol...
|
- Details
- Zach Klaassen speaks with Andrea Miyahira about the Prostate Cancer Foundation’s (PCF) significant contributions to the development of PSMA theranostics in prostate cancer. Celebrating its 30th anniversary, PCF has invested over $30 million in PSMA-related research, leading to FDA-approved imaging agents and therapies like Pluvicto. Dr. Miyahira outlines the foundation's future focus, including fu...
|
- Details
- Zach Klaassen hosts a discussion with Thomas Hope Jeremie Calais about a conference co-hosted by UCLA and UCSF, focusing on PSMA PET imaging and radioligand therapy. Scheduled for January 18th and 19th, 2024, at UCSF, the conference aims to educate healthcare professionals on interpreting PSMA PET results and managing patients effectively. The target audience includes both academic and private pra...
|
